Cyclophosphamide Suppliers & Bulk Manufacturers
Available Forms: Oral Tablet & Injection:
Available Strengths: Injection: 200 mg/2 mL (vial), 500 mg/5 mL (vial); Tablet: 25 mg, 50 mg ,100 mg
Reference Brands: Cytoxan®(US & EU), Endoxan®(EU)
Category:
Oncology Cancer Care
Cyclophosphamide is an intravenous chemotherapy drug used for breast cancer, ovarian cancer, non-Hodgkin lymphoma, leukemia, and autoimmune diseases. Available in IV (200 mg/2 mL, 500 mg/5 mL) and oral tablet (25 mg, 50 mg, 100 mg) formulations in the US and EU.
Cyclophosphamide is available in Oral Tablet & Injection:
and strengths such as Injection: 200 mg/2 mL (vial), 500 mg/5 mL (vial); Tablet: 25 mg, 50 mg ,100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Cyclophosphamide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Cyclophosphamide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Cyclophosphamide, marketed as Cytoxan® (US) and Endoxan® (EU), is a chemotherapy agent widely used in the treatment of cancers such as breast cancer, ovarian cancer, non-Hodgkin lymphoma, leukemia, and multiple myeloma. Additionally, it is used in the treatment of autoimmune diseases, including systemic lupus erythematosus. Available in IV infusion (200 mg/2 mL, 500 mg/5 mL) and oral tablet (25 mg, 50 mg, 100 mg) forms, Cyclophosphamide works as an alkylating agent to disrupt cancer cell DNA, offering significant opportunities for B2B oncology pharmaceutical companies in the US and EU markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing